Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER plus breast cancer.

被引：0
|
作者：
Liu, Renyan [1 ]
Pantelidou, Constantia [1 ]
Jadhav, Heta [1 ]
Shapiro, Geoffrey [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5649
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Mechanisms of resistance to CDK4/6 inhibition in ER plus breast cancer
    Lee, N. V.
    Eisele, K. J.
    Chionis, J.
    Yuan, J.
    Zhu, Z.
    Liu, C.
    Li, D.
    Olson, P. A.
    Fantin, V.
    Arndt, K. T.
    Shields, D. J.
    VanArsdale, T. L.
    CANCER RESEARCH, 2016, 76
  • [2] CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard
    Wolff, Antonio C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) : 1993 - 1995
  • [3] CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer
    Li, Qing
    Razavi, Pedram
    Li, Zhiqiang
    Paula, Arnaud F. Da Cruz
    Brogi, Edi
    Scaltriti, Maurizio
    Reis-Filho, Jorge S.
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Molecular determinants of resistance to CDK4/6 inhibition in ER plus breast cancer
    Luo, F.
    Cowley, G.
    Garraway, L.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S76 - S76
  • [5] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
    Martin, Miguel
    Garcia-Saenz, Jose A.
    Manso, Luis
    Llombart, Antonio
    Cassinello, Alejo
    Atienza, Manuel
    Ringeisen, Francois
    Ciruelos, Eva
    FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
  • [6] IMMUNOLOGICAL MECHANISMS OF RESISTANCE TO CDK4/CDK6 INHIBITORS IN BREAST CANCER
    Petroni, Giulia
    Gouin, Kenneth
    Martinez, Aitziber Buque
    Knott, Simon
    Formenti, Silvia
    Galluzzi, Lorenzo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A763 - A763
  • [7] Targeting CDK4 and CDK6 in cancer
    Goel, Shom
    Bergholz, Johann S.
    Zhao, Jean J.
    NATURE REVIEWS CANCER, 2022, 22 (06) : 356 - 372
  • [8] Targeting CDK4 and CDK6 in cancer
    Shom Goel
    Johann S. Bergholz
    Jean J. Zhao
    Nature Reviews Cancer, 2022, 22 : 356 - 372
  • [9] The CDK4/CDK6 inhibitor abemaciclib inhibits transcriptional targets which facilitate growth in ER plus breast cancer cells
    McNulty, Ann M.
    Burke, Teresa
    Dempsey, Jack A.
    Marchal, Christophe C.
    Schade, Andrew E.
    Szpurka, Hadrian P.
    Dowless, Michele S.
    Stephens, Jennifer
    Stephens, Jennifer
    Edmondson, Denise
    Stayrook, Keith
    Caldwell, William C.
    Buchanan, Sean
    Merzoug, Farhana F.
    Beckmann, Richard P.
    MOLECULAR CANCER RESEARCH, 2016, 14
  • [10] Targeting prostate cancer with the CDK4 and CDK6 inhibitor abemaciclib
    Torres-Guzman, Raquel
    Baquero, Carmen
    Patricia Ganado, Maria
    Marugan, Carlos
    Bian, Huimin
    Zeng, Yi
    Rama, Ramon
    Du, Jian
    Jose Lallena, Maria
    CANCER RESEARCH, 2020, 80 (16)
12345